Denbury Inc Warrants - Class A (18/09/2025) Stock (OTC: DNRWW)

Latest news for Denbury Inc Warrants - Class A (18/09/2025) (OTC:DNRWW) Stock

Denbury Inc Warrants - Class A (18/09/2025)

B of A Securities analyst John Murphy maintains Group 1 Automotive (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPI#NYSE">GPI</a>) with a Buy and lowers the price target from $445 to $435.

News

Price Target

Analyst Ratings

B of A Securities Maintains Buy on Group 1 Automotive, Lowers Price Target to $435

B of A Securities analyst John Murphy maintains AutoNation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AN#NYSE">AN</a>) with a Buy and raises the price target from $210 to $220.

B of A Securities Maintains Buy on AutoNation, Raises Price Target to $220

B of A Securities analyst John Murphy maintains Magna International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MGA#NYSE">MGA</a>) with a Buy and lowers the price target from $65 to $62.

B of A Securities Maintains Buy on Magna International, Lowers Price Target to $62

<a href="https://x.com/BrianSozzi/status/1815433523936780523" title="https://x.com/BrianSozzi/status/1815433523936780523">https://x.com/BrianSozzi/status/1815433523936780523</a>

Trading Ideas

Yahoo Finance Reporter Brian Sozzi Posts On X "Source familiar: Mattel is not in any deal talks, has not been approached"

B of A Securities analyst John Murphy maintains Lear (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEA#NYSE">LEA</a>) with a Buy and lowers the price target from $205 to $185.

B of A Securities Maintains Buy on Lear, Lowers Price Target to $185

B of A Securities analyst John Murphy maintains BorgWarner (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BWA#NYSE">BWA</a>) with a Buy and lowers the price target from $50 to $45.

B of A Securities Maintains Buy on BorgWarner, Lowers Price Target to $45

B of A Securities analyst John Murphy maintains American Axle &amp; Mfg Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXL#NYSE">AXL</a>) with a Underperform and raises the price target from $7 to $8.

B of A Securities Maintains Underperform on American Axle & Mfg Hldgs, Raises Price Target to $8

B of A Securities analyst John Murphy maintains Aptiv (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APTV#NYSE">APTV</a>) with a Buy and lowers the price target from $115 to $105.

APTV

B of A Securities Maintains Buy on Aptiv, Lowers Price Target to $105

B of A Securities analyst John Murphy maintains Adient (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADNT#NYSE">ADNT</a>) with a Buy and lowers the price target from $42 to $40.

ADNT

B of A Securities Maintains Buy on Adient, Lowers Price Target to $40

B of A Securities analyst Chase Mulvehill maintains Halliburton (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HAL#NYSE">HAL</a>) with a Buy and lowers the price target from $41 to $40.

B of A Securities Maintains Buy on Halliburton, Lowers Price Target to $40

Tilray Brands, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>) (TSX:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#TSX">TLRY</a>) announced on Monday that its Germany cannabis cultivation facility, Aphria RX GmbH, has obtained the first new cannabis cultivation license issued under MedCanG, Germany's new Cannabis Act.
<h3 class="wp-block-heading">Why It Matters</h3>
The new cannabis cultivation license allows Aphria RX to cultivate and manufacture a broad commercial range of medical cannabis, providing patients with better access to high-quality medical cannabis produced in Germany.
Denise Faltischek, the company's chief strategy officer and head of international, explained that the license allows Tilray to expand the range of treatment options available to patients. "We appreciate the trust that the German Government has placed in Tilray, and we are proud of our team for their groundbreaking work in medical cannabis cultivation and patient care," Faltischek said.
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/04/38297284/another-cannabis-pioneer-expands-in-germany-via-acquisition-as-experts-say-theres-no-stepping-ba">Another Cannabis Pioneer Expands In Germany Via Acquisition As Experts Say &#8216;There&#8217;s No Stepping Back&#8217; From Legalization Wave</a>
Aphria RX was awarded the most comprehensive license for the cultivation of medical cannabis in Germany from the&nbsp;German Federal Institute for Drugs and Medical Devices in May 2019. It was awarded a total of five lots (1,000 kgs) and was the only licensed producer in&nbsp;Germany&nbsp;with permission to grow all three strains of medical cannabis approved by the BfArM.
Tilray finalized its first harvest of medical cannabis grown in Germany via its German subsidiary&nbsp;Aphria RX in mid-2021.&nbsp;The medical cannabis was distributed to pharmacies in Germany on behalf of the German Cannabis Agency under the <a href="https://www.benzinga.com/markets/cannabis/21/07/21878991/tilrays-first-harvest-and-distribution-of-medical-cannabis-in-germany-successfully-completed">country's pharmaceutical and narcotic legal requirements.</a>
<h3 class="wp-block-heading">What's Next</h3>
With the new cannabis license, Tilray can fully utilize and maximize its growing capacity while also expanding its genetics to 31 approved strains from the previously approved three strains.
In the meantime, the new German law on recreational cannabis went into effect on April 1, <a href="https://www.benzinga.com/markets/cannabis/24/03/37891596/its-official-germanys-partial-cannabis-legalization-takes-effect-in-april">partially legalizing cannabis</a> by allowing adults over 18 to possess up to 25 grams of dried cannabis and grow three marijuana plants at home. 
Cannabis clubs became legal in Germany on July 1, 2024, ahead of the opening of the first marijuana social club a week later. Lower Saxony Minister of Agriculture Miriam Staudte announced in early July that the permit <a href="https://www.benzinga.com/markets/cannabis/24/07/39690787/first-cannabis-club-in-germany-opens-lawmaker-says-it-will-stem-illicit-marker-cops-say-the-oppo">was awarded by her office to Social Club Ganderkesee.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/10/29342857/aurora-tilray-better-positioned-than-other-cannabis-operators-for-germanys-imminent">Aurora &amp; Tilray Better Positioned Than Other Cannabis Operators For Germany&#8217;s Imminent Market Launch, Here&#8217;s Why</a></li>
</ul>
To learn more about cannabis innovation, com, join us at the 19th Benzinga Cannabis Capital Conference, coming to Chicago this Oct. 8-9. <a href="https://www.eventbrite.com/e/benzinga-capital-conference-cannabis-fall-2024-tickets-858948065787?aff=oddtdtcreator" target="_blank" rel="noreferrer noopener">Get your tickets now</a> before prices surge by following <a href="https://www.eventbrite.com/e/benzinga-capital-conference-cannabis-fall-2024-tickets-858948065787?aff=oddtdtcreator" target="_blank" rel="noreferrer noopener">this link</a>.

Cannabis

Regulations

TLRY

TSX:TLRY

Tilray Will Quintuple Its Medical Marijuana Production In Germany With New Cultivation License

B of A Securities analyst Shaun Kelley maintains RLJ Lodging (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RLJ#NYSE">RLJ</a>) with a Underperform and lowers the price target from $12 to $10.

B of A Securities Maintains Underperform on RLJ Lodging, Lowers Price Target to $10

B of A Securities analyst Shaun Kelley maintains Hilton Worldwide Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLT#NYSE">HLT</a>) with a Buy and raises the price target from $225 to $230.

B of A Securities Maintains Buy on Hilton Worldwide Holdings, Raises Price Target to $230

Ionis Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IONS#NASDAQ">IONS</a>) released results Monday from the completed multiple ascending dose (MAD) portion of the Phase 1/2 open-label study of ION582 in people with <a href="https://www.benzinga.com/pressreleases/24/07/n39879430/ionis-announces-positive-detailed-results-from-the-halos-study-of-ion582-in-people-with-angelman-s" target="_blank" rel="noreferrer noopener">Angelman syndrome (AS)</a>.
AS is a rare neurodevelopmental disorder caused by a loss of function in the maternal UBE3A gene. It affects an estimated 1 in 21,000 people worldwide.
The data demonstrated consistent and encouraging clinical improvement on assessing all functional domains, including communication, cognition, and motor function measures.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/05/39118220/ionis-pharmaceuticals-reveals-late-stage-donidalorsen-data-analyst-says-results-sho" rel="noreferrer noopener">Ionis Pharmaceuticals Reveals Late-Stage Donidalorsen Data, Analyst Says Results Show Competitive Hereditary Angioedema Profile</a>.
Overall, 97% of people in the medium and high dose groups saw an improvement in overall AS symptoms.
In the 51-patient HALOS study, ION582 showed favorable safety and tolerability at all dose levels.
Ionis plans to meet with regulators later this year to review and confirm its Phase 3 study design. This puts the company on track for a pivotal study initiation in the first half of 2025. 
William Blair writes that the update is a clear positive for Ionis, positioning ION582 as a key asset in its wholly owned portfolio after recently reacquiring sole rights from Biogen Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>).
William Blair reiterates the <a target="_blank" href="https://www.benzinga.com/quote/IONS/analyst-ratings" rel="noreferrer noopener">Outperform rating on Ionis</a>.
The analyst notes that the consistent improvements across various metrics in the robust dataset, which will likely be used as a primary endpoint for approval, boost confidence in the drug&#8217;s potential benefits.
While slightly behind a peer program from Ultragenyx Pharmaceutical Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RARE#NASDAQ">RARE</a>), Ionis has largely closed the development timeline gap and could be differentiated from a safety perspective, making ION582 an attractive asset for future growth given lack of approved therapies for the indication currently.
In the meantime, investors are expected to focus on the launch of Wainua (eplontersen) in collaboration with AstraZeneca Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>), and the potential approval and launch of the wholly-owned therapies olezarsen for familial chylomicronemia syndrome (PDUFA December 19, 2024) and donidalorsen for the prophylactic treatment of HAE (NDA expected to be filed this year).
The analyst believes the next 12 to 18 months could be transformative for Ionis due to the expansion of its marketed products. They also consider the company undervalued, especially in light of the potential of TTR silencers for TTR-cardiomyopathy, following Alnylam Pharmaceuticals Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) positive <a href="https://www.benzinga.com/general/biotech/24/06/39456940/alnylams-closely-watched-phase-3-heart-disease-trial-of-vutrisiran-hits-primary-endpoint-shares-s" target="_blank" rel="noreferrer noopener">HELIOS-B trial results for vutrisiran</a>.
Price Action: IONS stock is up 4.50%, trading at $49.97 at last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/05/38878003/tale-of-two-ionis-partnered-neurology-focused-early-stage-assets-biogen-discontinues-one-decides-" target="_blank" rel="noreferrer noopener">Tale Of Two Ionis-Partnered Neurology-Focused Early Stage Assets-Biogen Discontinues One, Decides Not To Exercise Licensing Option For Another</a>.</li>
</ul>

Analyst Color

Biotech

Health Care

Reiteration

Movers

General

ALNY

BIIB

IONS

RARE

Ionis' Rare Development Disorder Drug Candidate 'Could Be Differentiated' From Peer Ultragenyx: Analyst

B of A Securities analyst Rafe Jadrosich maintains PulteGroup (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHM#NYSE">PHM</a>) with a Buy and raises the price target from $135 to $138.

B of A Securities Maintains Buy on PulteGroup, Raises Price Target to $138

Sometimes markets are hard to read. There may be no clear leadership. Traders are confused. They don't know what to watch.
But sometimes markets are easy to read. There may be just one or two stocks in the driver's seat. What happens with them can influence the direction of the broader markets. That's why Microsoft Corp&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) is our stock of the day.
Nvidia gets most of the recent media attention. But at 7.02%, Microsoft is the biggest stock in the S&amp;P 500. This means what happens here could affect other stocks.
As you can see on the chart, <a href="https://www.benzinga.com/quote/MSFT">Microsoft</a> found support around the $432.50 level. As for now, it is holding. But if the shares break this support, it could bring the rest of the market down with it.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="599" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/22114111/1-20-1024x599.png" alt="Microsoft (MSFT) bounces off of support." class="wp-image-449088" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/22114111/1-20-1024x599.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/22114111/1-20-300x176.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/22114111/1-20-768x450.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/22114111/1-20.png 1042w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read Also: <a href="https://www.benzinga.com/insights/news/24/07/39886344/exploring-the-competitive-space-microsoft-versus-industry-peers-in-software">Exploring The Competitive Space: Microsoft Versus Industry Peers In Software</a>
In March and May, <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">Microsoft </a>hit resistance around $432.50. Each time was followed by a selloff. There is no doubt that many of the traders and investors who sold at this resistance were glad they did.
But then in June, the shares rallied through this resistance and moved higher. When this happened, some of those who sold came to regret their decision to do so.
Some number of them decided to buy their shares back. But they don't want to pay more than the price they sold. They will only buy them at the same price.
So, on Friday when the stock finally returned to the price level that had previously been resistance, they placed buy orders. And there were so many of these remorseful sellers placing these orders that it created support at the price that was resistance.
For now, this support is holding. There is a small rebound underway.
But if the shares trade below this level, traders will say the support has been &#8220;broken.&#8221; This would illustrate an important supply and demand dynamic.
It will mean that the people who created the support with their buy orders have left the market. Their orders were either canceled or finished.
With this large amount of demand or buy interest out of the way, sellers will need to force the price lower to attract buyers back into the market. This could cause a new downtrend to form.
And if the biggest stock in the entire market heads lower, others may follow.
Read Next: • <a href="https://www.benzinga.com/news/earnings/24/07/39880691/wall-street-set-to-rebound-amid-hopes-of-strong-earnings-political-uncertainty-caused-by-biden-step">Wall Street Set To Rebound Amid Hopes Of Strong Earnings: &#8216;Political Uncertainty&#8217; Caused By Biden Stepping Down Could Be &#8216;Catalyst For Market Volatility,&#8217; Says Analyst</a>
Photo: Shutterstock

Technicals

Tech

MSFT

Stock Of The Day: If There's One To Watch, It's Microsoft

B of A Securities analyst Ebrahim Poonawala maintains Fifth Third Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FITB#NASDAQ">FITB</a>) with a Buy and raises the price target from $42 to $45.

FITB

B of A Securities Maintains Buy on Fifth Third Bancorp, Raises Price Target to $45

<a href="https://register.epo.org/application?number=EP19805439" title="https://register.epo.org/application?number=EP19805439">https://register.epo.org/application?number=EP19805439</a>

CYTH

Cyclo Therapeutics Has Been Granted European Patent Number EP3873604 Titled "METHODS FOR TREATING ALZHEIMER'S DISEASE WITH HP-[BETA]-CYCLODEXTRIN"

B of A Securities analyst Ken Hoexter maintains Westinghouse Air Brake (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAB#NYSE">WAB</a>) with a Buy and raises the price target from $183 to $184.

B of A Securities Maintains Buy on Westinghouse Air Brake, Raises Price Target to $184

Providing a diverse range of perspectives from bullish to bearish, 4 analysts have published ratings on Reynolds Consumer Prods (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REYN#NASDAQ">REYN</a>) in the last three months.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $29.0, a high estimate of $30.00, and a low estimate of $28.00. Holding firm without variation, the current average remains at the previous average price target. 
<img src="https://www.benzinga.com/files/images/story/2024/1721667690_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
A comprehensive examination of how financial experts perceive Reynolds Consumer Prods is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Andrea Teixeira</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$29.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Lauren Lieberman</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$28.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Lauren Lieberman</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$29.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Brian McNamara</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Hold</td>
<td>$30.00</td>
<td>$29.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Reynolds Consumer Prods. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Reynolds Consumer Prods compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Reynolds Consumer Prods's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Reynolds Consumer Prods's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/REYN/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Reynolds Consumer Prods analyst ratings.</a>
<h2>All You Need to Know About Reynolds Consumer Prods</h2>
Reynolds Consumer Products Inc is a provider of household products. The firm is engaged in the production and sales of cooking products, waste and storage products, and tableware. It operates through four reportable segments namely, Reynolds Cooking and Baking, Hefty Waste and Storage, Hefty Tableware, and Presto Products. Reynolds Cooking and Baking segment produce branded and store brand aluminum foil, disposable aluminum pans, parchment paper, freezer paper, wax paper, butcher paper, plastic wrap, baking cups, oven bags and slow cooker liners.
<h3>Key Indicators: Reynolds Consumer Prods's Financial Health</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Negative Revenue Trend: Examining Reynolds Consumer Prods's financials over 3 months reveals challenges. As of 31 March, 2024, the company experienced a decline of approximately -4.69% in revenue growth, reflecting a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Consumer Staples sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of 5.88%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Reynolds Consumer Prods's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of 2.47%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Reynolds Consumer Prods's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of 1.02%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Reynolds Consumer Prods's debt-to-equity ratio is below the industry average. With a ratio of 0.96, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>How Are Analyst Ratings Determined?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Comments

Denbury Inc Warrants - Class A (18/09/2025)

News

Latest news for Denbury Inc Warrants - Class A (18/09/2025) (OTC:DNRWW) Stock